Finzati - Logo
GLMD logo

Galmed Pharmaceuticals Ltd.

GLMDBiotechnology
$4.02
0.00 (0.00%)
EarningsSep 4, 11:12 AM UTC
New financial eventQ2 2026Negative

Galmed Pharmaceuticals Ltd. has reported Q2 2026 financial results

The latest report contains several weaker financial signals that deserve attention. Growth, profitability, cash generation, or financial strength may have deteriorated. The report may attract increased investor attention and price volatility.

Finzati signal
Caution warranted
Sep 4, 11:12 AM UTC
Changed
-9.14%
Net income
Changed
-67.74%
Free cash flow
Changed
-44.51%
Cash
What changed
Net income declined 9.1%, showing weaker profitability.
Free cash flow declined 67.7%, indicating pressure on cash generation.
Cash and short-term investments declined 44.5%.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Sep 4, 2026, 11:12 AM UTCLast profile update: Sep 4, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.02
Change0.00%
Shares Out952.17K
Market Cap$3.83M
Enterprise Value$-7.48M
52W Range3.29 - 13.20
Beta0.67
P/E-0.34
P/B0.30
P/FCF-0.45
EV/EBITDA0.75
EV/FCF0.88

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score
Manageable debt level · 0Healthy liquidity · 6.55Weak profitability

Analyst view

Analyst sentiment and price target

GLMD
Analyst sentiment
Based on 16 analyst votes · 2026-09-04
81/100
Bullish
Bullish
10
Hold
6
Bearish
0

Company Overview

IPO: 3/12/2014
Industry: Biotechnology
P/B i: 0.30
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.00
Current Ratio: 6.55
Quick Ratio: 6.55
Status: Good
🧾

No insider activity

No recent insider transactions available.